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 Abstract 
Anti-cancer immunotherapies demand optimal epitope targets, which could include 
proteasome-generated spliced peptides if tumor cells were to present them. Here, we 
show that spliced peptides are widely presented by MHC class I molecules of colon and 
breast carcinoma cell lines. The peptides derive from hot spots within antigens and 
enlarge the antigen coverage. Spliced peptides also represent a large number of antigens 
that would otherwise be neglected by patrolling T cells. These antigens tend to be long, 
hydrophobic, and basic. Thus, spliced peptides can be a key to identifying targets in an 
enlarged pool of antigens associated with cancer. 
 
  
  
Introduction 
Adoptive T cell therapy (ATT) uses CD8+ T lymphocytes to selectively recognize and 
eliminate cancer cells. Ideal markers for cancer cell recognition are epitopes either 
carrying cancer-driver somatic mutations or presenting cancer-germline antigens. The 
number of these epitopes is, however, limited by the number of known cancer-germline 
genes, by the mutation frequency, and by the fact that epitopes need to have specific 
motifs to be presented on major histocompatibility complex class I (MHC-I) molecules 
and to pass all steps of the antigen presentation pathway. The identification of targetable 
tumor-specific epitopes is therefore one of the most challenging and yet promising quests 
in anti-cancer immunotherapies (1,2). 
MHC-I-bound epitopes are generally produced by the proteasome, which can break 
proteins and release peptide fragments or re-ligate them in a process called proteasome-
catalyzed peptide splicing (PCPS) (3). PCPS forms new (spliced) peptides with sequences 
that do not recapitulate the parental protein and is driven and regulated by factors that 
have been only partially determined (4-8). Despite our limited knowledge about PCPS, 
spliced peptides constitute a large portion of the antigenic peptide pool for human EBV-
transformed cell lines and primary fibroblasts (9) and can be presented by MHC-I 
complexes in amounts comparable to canonical non-spliced peptides (9,10). As the non-
spliced epitopes, proteasome-generated spliced epitopes can trigger in vivo CD8+ T cell-
mediated responses toward tumor-associated or pathogen-derived antigens (10-12) and 
can be targets for effective anti-cancer ATT (13,14).  
At which magnitude could targeting spliced epitopes be an opportunity for ATTs is an 
open question with relevance for translational medicine. On one hand, the theoretically 
large variety of spliced peptide sequences suggests that recurrent driver mutations, 
which could not be efficiently presented on predominant MHC-I variants by non-spliced 
peptides because of sequence limitations, could be conversely presented by spliced 
peptides (15). The preliminary observation that a large portion of antigens is represented 
at the surface of nontumor cells only by spliced peptides (9) suggests that PCPS could 
permit the presentation by MHC-I molecules of so far overlooked tumor-associated 
antigens. On the other hand, the few examples of CD8+ T cells specific for spliced 
epitopes described so far - derived from tumor-associated antigens (4,7,10,13,14,16) – 
might call into question the relevance of PCPS in generating a large number of tumor-
associated epitopes. Although this question could have been already answered by 
studying the antigenic peptides bound to the MHC-I molecules – i.e. the MHC-I 
immunopeptidome - of cancer cell lines, technical difficulties inherent in the PCPS itself 
hindered that approach (15). These difficulties have been resolved through development 
of a strategy for the identification of spliced peptides in the MHC-I immunopeptidome by 
mass spectrometry (MS) (9). With that method, we could identify a portion of the 
immunopeptidome, which consisted of spliced peptides generated by proteasomal binding 
 of two peptide fragments derived from the same molecule by cis PCPS (Supplementary 
Fig. S1) and separated in the antigen by no more than 20 residues (9). That study, 
which found that an unexpectedly large frequency of spliced peptides are available for T 
cell recognition, demonstrated promise aid for the identification of novel targets for anti-
cancer immunotherapy. Here we have developed a novel method for the identification of 
spliced peptides in the immunopeptidome, we have applied that approach to cancer cells 
and proved that PCPS enlarges the antigenic landscape in cancer cells. 
 
Materials & Methods 
Further details of the methods and the explanations of the outcomes are described in 
Supplemental Experimental Procedures section. 
Cell lines  
HCT116 and HCC1143 are cell lines derived from colon or breast carcinoma, respectively 
(Supplementary Table S1). HCC1143 have been grown in RPMI medium with 10 % 
FCS, 2 mM glutamin and PenStrep, 1xMEM, 1xNaPyruvat, in 5 % CO2 atmosphere at 37° 
C. They have been been purchased from ATCC one years prior the use, they have been 
tested for mycoplasma and have not been re-authenticated. 
Peptide synthesis and proteasome purification.  
The polypeptide substrates have been synthesized using Fmoc solid phase chemistry. The 
sequence enumeration for the substrate polypeptides is reported in Supplementary 
Table S2. The mutated peptides (neoepitopes) identified in the MHC-I 
immunopeptidome of the HCT116 cell line and in the in vitro digestions of the synthetic 
substrates by purified proteasome, are reported in Supplementary Table S3. 
20S proteasome has been purified from peripheral blood of a healthy donor, as 
previously described (10). Proteasome concentration has been measured by Bradford 
staining and verified by Coomassie staining in a SDS-PAGE gel. The purity of 
standardized proteasome preparations has been previously shown (17). 
In vitro digestions and MS analysis.  
Synthetic polypeptides (20 M) have been digested by 3 g 20S proteasome in 100 l 
TEAD buffer for 20 h at 37°C as previously described (17). In vitro digestion samples 
have been measured by MS as following: 10µl digested sample has been concentrated 
for 5 min on a trap column (PepMap C18, 5 mm x 300 μm x 5 μm, Particel Size 100Ǻ, 
Thermofisher Scientific) with 2:98 (v/v) acetonitrile/water containing 0.1% (v/v) TFA at 
a flow rate of 20 μl/min and then analyzed by nanoscale LC-MS/MS using an Ultimate 
3000 and Q Exactive Plus mass spectrometer (ThermoFisher Scientific). The system has 
comprised a 75 µm i.d. × 250 mm nano LC column (Acclaim PepMap C18, 2 μm; 100 Å; 
ThermoFisher Scientific). The mobile phase (A) consisted of 0.1% (v/v) formic acid in 
water, and (B) 80:20 (v/v) acetonitrile/water containing 0.1% (v/v) formic acid. The 
elution has been carried out using a gradient 3-50% B in 30 min with a flow rate of 300 
nl / min. Full MS spectra (m/z 200-2000) have been acquired on a Q Exactive at a 
 resolution of 70,000 (FWHM) followed by a data-dependent MS/MS of the top10 
precursor ions (resolution 17,500, 4-8+ charge state excluded, 1µscans). Fragment ions 
have been generated in a HCD cell and detected in an Orbitrap Mass Analyzer. Dynamic 
exclusion has been enabled with 30-s exclusion duration. The maximum ion injection 
time for MS scans has been set to 50 ms and for MS/MS scans to 80 ms. Background 
ions at m/z 391.2843 and 445.1200 have acted as lock mass. Peptides have been 
identified using the search engine Mascot version 2.6.1 (Matrix Science). The MS 
outcomes of the in vitro digestions of the synthetic substrates have been analyzed with 
the aim of identifying target peptides as previously described (18). Compared to the 
analysis method used for the analysis of the MHC-I immunopeptidomes, no restrictions 
for either the peptide product length or the intervening sequence length have been 
applied. 
Extraction, processing, and analysis of proteins (> 30 kDa) from the HCC1143 cell lysate.  
HCC1143 cell pellet (3*106) has been lysed in 6 M urea/2 M thiourea in 10 mM HEPES 
(pH 8.0) by repeated thawing and freezing. The samples have been centrifuged at 
20,000 g for 15 min at 4°C. Protein concentration in the supernatant have been 
quantified by BCA. Proteins larger than 30 kDa have been separated by NanoSep 
Centrifugal 30 kDa (Pall Life Sciences), centrifuging the sample for 15 min at 14,000 g. 
Then, we diluted 15 g protein in ABC buffer (50 mM ammoniumbicarbonate, 6 mM DTT, 
5% ACN). The sample was then alkylated by the addition of iodoacetamide (12 mM final 
concentration) and left in the dark at room temperature for 30 min. Proteins were 
digested by 0.3 g Lys-C for 3 h at room temperature, further diluted in ABC buffer and 
digested by 0.3 g trypsin overnight at room temperature. The sample was then purified 
by SepPak C18 (Waters) and eluted with a buffer 80% ACN 0.1 % TFA and concentrated 
by speedvac. 10µl digested sample was concentrated for 4 min on a trap column 
(PepMap C18, 5 mm x 300 μm x 5 μm, Particel Size 100Ǻ, ThermoFisher Scientific) with 
2:98 (v/v) acetonitrile/water containing 0.1% (v/v) TFA at a flow rate of 20 μl/min and 
then analyzed by nanoscale LC-MS/MS using an Ultimate 3000 and Q Exactive Plus mass 
spectrometer (ThermoFisher Scientific). The system comprised a 75 µm i.d. × 250 mm 
nano LC column (Acclaim PepMap C18, 2 μm; 100 Å; ThermoFisher Scientific). The 
mobile phase consisted of (A) 0.1% (v/v) formic acid in water, and (B) 80:20 (v/v) 
acetonitrile/water containing 0.1% (v/v) formic acid. The elution was carried out using a 
gradient 3-30% B in 85 min with a flow rate of 300 nl/min. Full MS spectra (m/z 200-
2000) was acquired on a Q Exactive Orbitrap at a resolution of 70,000 (FWHM) followed 
by a data-dependent MS/MS of the top10 precursor ions (resolution 17,500, 4-8+ charge 
state excluded, 1µscans). Fragment ions were generated in a HCD cell and detected in an 
Orbitrap Mass Analyzer. Dynamic exclusion was enabled with 20-s exclusion duration. 
The maximum ion injection time for MS scans was set to 50 ms and for MS/MS scans to 
2000 ms. Background ions at m/z 391.2843 and 445.1200 acted as lock mass. Peptides 
were identified with the search engine Mascot version 2.6.1 (Matrix Science), applying 
 the same method used for the MHC-I immunopeptidome analysis (described below). 
MHC-I–peptide binding affinity.  
The binding affinity of two neoepitopes identified in the HCT116 MHC-I 
immunopeptidome to the four MHC-I variants (HLA-A*01:01, -A*02:01, -B*45:01, -
B*18:01) of the HCT116 cell line was measured using purified MHC-I molecules, as 
described elsewhere (9). 
Identification of spliced and non-spliced peptides  
The analysis of the MS datasets, generated from the immunopeptidome of the cell lines 
HCC1143 and HCT116 published by Bassani-Sternberg et al. (19), was carried out with 
Mascot version 2.6.1 (Matrix Science). MS/MS scans were searched with no enzyme 
specificity and 6 ppm peptide precursor mass tolerance, 20 ppm MS/MS mass tolerance 
and HCD fragmentation.  
We computed for each protein entry in the human Swissprot database all 9 to 12-mer 
normal and reverse cis spliced peptides with a maximum intervening sequence length of 
25 residues (see Supplementary Fig. S1 for the PCPS nomenclature and 
Supplementary Fig. S2A,B for the peptide identification pipeline). All spliced sequences 
that could be generated by simple peptide-bond hydrolysis (i.e. non-spliced peptides) of 
any human protein were removed from the database. For each resulting spliced peptide, 
the molecular weight (MW) was computed. Similarly, all 9-12mer non-spliced peptides 
and their MWs were computed. We then matched the observed precursor masses in the 
MS data with the MW of all theoretical spliced and non-spliced peptides that could be 
expected from an instrument with an accuracy of 6 ppm, and thereby reduced the overall 
database to a dataset-specific database. In order to generate a database that has a 
structure similar to that of the human proteome and to make our search strategy as 
similar as possible to previous studies, we transformed our spliced and non-spliced 
databases into the structure of the human proteome database. We concatenated the N-
mer spliced peptide sequences to longer sequences, thereby generating new ‘protein’ 
entries, which have a length distribution that followed that of the human proteome. For 
easier annotation, we concatenated spliced and non-spliced sequences in separate 
‘proteins’. Based on this combined spliced and non-spliced database structure, we then 
computed the decoy database via randomization of the ‘protein’ sequences, while 
ensuring that none of the target N-mer spliced and non-spliced sequences is present in 
the decoy database. All spectra were simultaneously searched against the spliced, non-
spliced and decoy database using the Mascot search engine. The search results were 
extracted from Mascot and filtered using an ion score cut-off, which resulted in 1% FDR. 
Merging short peptides into new ‘proteins’ results in several database entries that are 
artificial junctions between the short peptides; these are neither spliced peptides nor 
non-spliced peptides. We have considered these database entries as decoy sequences, in 
case they matched an MS/MS spectrum. 
 The protocol described so far is identical with the analysis protocol described in Liepe et 
al. (9). In order to further increase the certainty in the identification of spliced peptide 
sequences, we have here introduced a minimum delta score () of 0.3, which describes 
the relative deviation of a spliced peptide ion score (s1) from a spliced or non-spliced 
peptide ion score (s2):  = 1-s2/s1, where s1 < s2. Applying this delta score avoids the 
annotation of MS/MS spectra with spliced peptide sequences that are not certain because 
very similar (spliced or non-spliced) sequences could be almost equally well matched. If  
< 0.3 between two spliced peptide sequences, we did not annotated the MS/MS 
spectrum. If  < 0.3 between a spliced and a non-spliced peptide, we considered the 
non-spliced peptide as the correct assignment (given there have been no other higher 
scored sequences for this MS/MS spectrum). By doing so, we have made the 
conservative assumption that a non-spliced peptide with a score of less than 30% 
difference to a spliced peptide score is more likely to be the correct assignment of this 
MS/MS spectrum.  
Since it is almost impossible to distinguish leucine (L) and isoleucine (I) from each other, 
we have incorporated this uncertainty in our pipeline, by checking that a spliced peptide 
sequence carrying either L or I could not be explained by a non-spliced peptide sequence 
through exchange of I and L. 
We introduced a last step in the pipeline by comparing the predicted MS-HPLC retention 
time (or more precisely the hydrophobicity) of the peptides with the MS-HPLC retention 
time of the MS/MS spectrum assigned to the corresponding peptide. The hydrophobicity 
of peptides can be predicted depending on the MS separation system and is correlated 
with the measured peptide retention times. We have made use of such a predictor – i.e. 
SSRCalc, (20) - and predicted the hydrophobicity of all assigned non-spliced peptides. 
Assuming that the non-spliced peptide assignments are correct, we have computed the 
running average of the predicted hydrophobicity as a function of the measured non-
spliced peptide retention time and detect the observed variance. We then applied this 
running average and variance to the spliced peptides. We removed all spliced peptide 
assignments that have predicted hydrophobicity, which shows a larger discrepancy to the 
running average of non-spliced peptides than the variance of the non-spliced peptides. 
This retention time filter is only applied to remove possibly wrong spliced peptide 
assignments. No non-spliced peptides were removed, regardless of their predicted 
hydrophobicity. 
Peptide sequence assignment using semi-inverted databases 
To estimate the possible false assignment rate of spliced and non-spliced peptide 
sequences in the MHC-I immunopeptidome, we generated artificial spliced peptide 
databases in which the sequence of either the N-terminal splice-reactant or the C-
terminal splice-reactant was inverted. These semi-inverted databases contain almost the 
same number of sequences as the spliced human proteome database. Partially inverting 
sequences does not alter the molecular weight of the sequence. Therefore, the m/z-
 matched semi-inverted databases contain as many entries as the m/z-matched spliced 
human proteome database. Since the latter two types of databases are constructed in 
similar ways, all database entries contain an N-mer long sequence that is identical to a 
peptide sequence found in the human proteome. If the identification of spliced peptides 
were due to an artifact appearing in the database construction and/or size, we would 
expect to identify similar numbers of semi-inverted peptide sequences as spliced 
peptides. 
The semi-inverted databases were used to analyze one technical replicate (sample 
20120617_EXQ0_MiBa_SA_HCT116_2_mHLA_2hr.raw) of the HCT116 
immunopeptidome. The number of identified semi-inverted peptides was compared to 
the total number of peptides identified (sum of semi-inverted sequences and non-spliced 
peptides). Among the identified sequences, we checked which sequences could be spliced 
peptides with intervening sequences longer than 25 residues (which is the restriction we 
applied for the construction of the spliced human proteome database in our pipeline). In 
parallel, we adopted a similar strategy, in which we generated two databases where the 
sequences of either N-terminal or C-terminal portions of the non-spliced peptides were 
inverted. Since non-spliced peptides do not consist of two splice-reactants, of which we 
could invert one of the splice reactants, we randomly sampled an artificial peptide 
splicing site based on a uniform distribution along the peptide sequence. Finally, we 
searched the same technical replicate of the HCT116 immunopeptidome against the non-
spliced proteome database together with the semi-inverted non-spliced database and 
considered any assignment of sequences present in the semi-inverted databases as 
random. 
Mutations, neoepitopes and antigen presentation in the MHC-I immunopeptidome 
To evaluate the prevalence of mutated antigens presented by MHC-I complexes, we 
calculated the number of expressed mutated and non-mutated antigens, which are 
represented by spliced peptides only, non-spliced peptides only, or both. The total 
number of expressed proteins is based on the data published by Klijin et al (21) and the 
mutations identified by RNAseq in independent studies (22). Further details are reported 
in Supplemental Experimental Procedures. 
The spatial localization of the spliced and non-spliced peptides within the 3D structures of 
the antigens CHMP7 and RBBP7 were graphically presented using PyMol. The tertiary 
protein structure of CHMP7 and RBBP7 was predicted using I-Tasser (23).  
Quantification 
Quantification of the amount of spliced and non-spliced peptides in the 
immunopeptidomes by label-free MS was done as previously described (9). Briefly, we 
extracted the MS ion current peak area for each identified peptide (using Mascot 
Distiller’s label-free quantification tools) and used this information to estimate the 
distribution of the amount of the spliced and non-spliced peptides. Potential bias of this 
method due to differences in the chemical features of spliced compared to non-spliced 
 peptides has been previously excluded (9). Further details are reported in Supplemental 
Experimental Procedures. 
Statistical analysis. 
If not described otherwise, all statistical tests have been done in R and differences in 
distributions have been tested using the Kolmogorov-Smirnov test. Where appropriate, 
p-values have been adjusted with Bonferroni correction. We computed the odds ratio 
(OR) of mutated antigens being represented by peptides vs. non-mutated antigens being 
represented by peptides by performing Fisher’s exact ratio test. In this latter statistical 
analysis, we distinguished between all antigens represented by any non-spliced peptide 
and antigens represented by any spliced peptide. Correlation analysis was conducted 
using Pearson correlation coefficient, where the test statistic follows a t distribution. 
Dataset availability 
The MHC-I immunopeptidome datasets have been obtained from the PRIDE archive 
(identifier: PXD000394; files:  
20120321_EXQ1_MiBa_SA_HCC1143_1.raw, 
20120321_EXQ1_MiBa_SA_HCC1143_2.raw, 
20120322_EXQ1_MiBa_SA_HCC1143_1_A.raw, 
20120515_EXQ3_MiBa_SA_HCT116_mHLA-1.raw, 
20120515_EXQ3_MiBa_SA_HCT116_mHLA-2.raw, 
20120617_EXQ0_MiBa_SA_HCT116_1_mHLA_2hr.raw, 
20120617_EXQ0_MiBa_SA_HCT116_2_mHLA_2hr.raw) or the Datadryad.org archive 
(doi:10.5061/dryad.r984n) and were generated by Bassani et al. (19), Mommen et al. 
(24). The cell source characteristics are described in Supplementary Table S1. The 
RNAseq datasets for the HCT116 and HCC1143 cell lines were obtained from Klijn et al. 
(21). The mutations’ database for the HCC1143 and HCT116 refers to the Cosmic 
database (version 17/8/2016) (22). 
All other MS files (.mgf and/or .RAW) generated for the study, the peptide spectrum 
matches for the immunopeptidome datasets and the mutation lists of the two cancer cell 
lines are available at the Mendeley database: http://dx.doi.org/10.17632/y2cvb5nvgn.1 
(see Supplementary Table S4). 
Software and computing infrastructure. 
All algorithms, spliced and non-spliced peptide databases, decoy databases and data 
analysis and data plotting tools have been implemented in R on a Linux cluster system 
with 120 CPU-cores used for the construction of the entire human spliced peptide 
database (total data volume of database stored as binary RData files: 107 Gb) and for 
the construction of all dataset specific databases (total data volume of database stored 
as binary RData files per MS RAW file: 45 Gb; total data volume of database stored as 
FASTA file per MS RAW file: 447 Gb; Mascot compiled databases results in approximately 
1.5 Tb storage space needed per RAW file analysis). 
 The scripts for the MHC-I spliced peptides’ database generation are available at the 
Mendeley database: http://dx.doi.org/10.17632/y2cvb5nvgn.1. 
Commercial Software: MS RAW data were converted into mascot generic file format 
using Mascot Distiller. Using the Mascot search engine (standard 1cpu license, uses 4 
CPU-cores in parallel), the total search time per replicate of the HCC1143 and the 
HCT116 cell lines, respectively, was approximately 15 days (this varied depending on 
dataset analyzed). 
The 3D representation of the 2 antigens represented by neoepitopes was carried out 
using the software I-Tasser (23) to predict the tertiary protein structure, and by Pymol 
for graphic visualization (The PyMOL Molecular Graphics System, Version 1.7.4 
Schrödinger, LLC). 
 
Results 
SPI-delta method detects MHC-I spliced immunopeptidome of cancer cell lines 
To investigate the spliced immunopeptidome of cancer cells, we developed the SPI-delta 
(Spliced Peptide Identifier - version delta) method (Supplementary Fig. S2). In 
particular, we allowed, in the new human spliced proteome database, spliced 9-12mer 
peptides generated with an intervening sequence between the splice-reactants of 25 
residues or less (see Supplementary Fig. S1 for PCPS nomenclature), allowing entries 
5 residues longer than the previous version of the method (9). We introduced this 
modification because the study on MHC-I immunopeptidomes of nontumoral human cells 
did not show a prevalence of spliced peptides with short intervening sequences (9). We 
also introduced a minimum delta score to identify a peptide as spliced peptide. We 
included a final step in the pipeline to remove from the final annotation all spliced 
peptides that have a MS-HPLC retention time discordant to what is expected (see 
Materials & Methods for details and Supplementary Fig. S2). 
We applied SPI-delta to the MHC-I immunopeptidomes of the HCT116 and HCC1143 cell 
lines. These cell lines were chosen because they derive from two of the most common 
and lethal tumors in the world (i.e. colon and breast cancer, respectively), and colorectal 
cancer can be cured by ATT by targeting neoepitopes (25).  
Among the assigned sequences of the two cancer cell lines’ immunopeptidomes, 1230 
peptides are spliced peptides, which account for 23.6% of the variety of the 
immunopeptidomes (Fig. 1A, Supplementary Table S5). We could search the 
immunopeptidome samples without considering cell-specific mutations detected in these 
two cancer cell lines (21,22), and not allowing the identification of the most common 
post-translational modification (PTMs) of non-spliced peptides. In this case, the absolute 
number of both spliced and non-spliced peptide identifications, as well as the relative 
frequency of spliced peptides is increased (Fig. 1A). Including PTMs in the MS data 
analysis increases the target and therefore the decoy database, which results in more 
stringent cut-offs for peptide identifications to ensure 1% false discovery rate (FDR). As a 
 consequence, fewer peptides are identified. Ignoring PTMs can result in the assignment 
of MS/MS spectra as spliced peptides even though the better assignment would be a 
post-translationally modified non-spliced peptide. This phenomenon explains the higher 
frequency of spliced peptides when we do not consider PTMs.  
When investigating the spliced peptide quantity, we observed that, on average, the MHC-
I-restricted spliced peptides are present in smaller amounts than non-spliced peptides: 
spliced peptides are represented by fewer molecules than non-spliced peptides, although 
they represent 19.3% and 19.6% of the bulk of peptide molecules detected in the 
HCT116 and HCC1143 immunopeptidomes, respectively (Fig. 1B).  
Aspects of the label-free quantification method applied to estimate the spliced and non-
spliced peptide amounts are further described in Supplemental Experimental Procedures 
and Supplementary Fig. S3A-G, where further general features of the spliced peptide 
pool are also reported.  
 
Validation of the cancer cell immunopeptidome assignment 
One of the concerns about spliced peptide identification in the immunopeptidome is the 
large size of the theoretical spliced peptide database, which might result in false 
sequence assignments despite the strict FDR of 1% and quality control steps in the SPI-
delta pipeline. To test this hypothesis, we carried out two control experiments.  
In the first experiment, we generated a proteasome-independent complex peptide 
mixture by LysC and trypsin degradation of the HCC1143 intracellular proteome. We 
analyzed this dataset following the same protocol applied to the immunopeptidome, 
thereby using the same size of the spliced peptide database used for the 
immunopeptidome analysis. The sample has thousands of 9-12mer peptides and an ion 
charge distribution similar to the immunopeptidomes (Fig. 1C-E). The sample somewhat 
mimics the cancer cell immunopeptidome datasets. Nonetheless, only 2.4% of peptides 
are annotated as spliced peptides (Fig. 1C). 
In the second experiment, as a representative example, we considered the technical 
replicate of the HCT116 immunopeptidome in which we identified the largest number of 
peptides. We analyzed it using the spliced and non-spliced human proteome databases to 
match the peptide precursors in the dataset (m/z matching). For those spliced peptide 
precursors that have been matched, we generated two databases, in which the sequence 
of all N-terminal or C-terminal splice-reactants have been inverted. To note, those semi-
inverted databases each are approximately the size of the normal spliced peptide 
database generated to analyze this dataset. The HCT116 immunopeptidome dataset was 
then re-analyzed using the non-spliced proteome database together with either the 
inverted N-terminal or inverted C-terminal splice-reactant databases. Any assignment of 
sequences present in the semi-inverted databases is considered as randomly assigned. In 
parallel, we generated two databases where the sequences of all possible N-terminal or 
C-terminal portions (of randomly chosen length) of the non-spliced peptides have been 
 inverted. We then searched the same technical replicate of the HCT116 
immunopeptidome against the non-spliced proteome database together with the semi-
inverted non-spliced database and considered any assignment of sequences present in 
the semi-inverted databases as randomly assigned. These additional four searches 
provide us with an estimation, in the same dataset used for the MHC-I immunopeptidome 
identification, of the number of potentially wrongly assigned spliced peptides, depending 
on the database size. By searching against the semi-inverted spliced peptide databases, 
we assigned 4.2% C-terminally inverted spliced peptides and 3.6% N-terminally inverted 
spliced peptides to MS/MS spectra relative to the total number of peptides assigned (Fig. 
1F). Some of the sequences present in the semi-inverted databases can, however, be cis 
spliced peptides with the intervening sequence longer than 25 residues. If we do not 
consider these latter semi-inverted peptides, 3.0% of C-terminally inverted spliced 
peptides and 2.5% of N-terminally inverted spliced peptides are assigned. Furthermore, 
we assigned 0.2% of C-terminally inverted non-spliced peptides and 1.5% of N-
terminally inverted non-spliced peptides to MS/MS spectra relative to the total number of 
peptides assigned (Fig. 1F). 
These results show that the number of identified spliced peptides in the cancer 
immunopeptidomes is higher than that of the negative controls, confirming that the 
spliced peptide identification in the MHC-I immunopeptidome is not an artifact due to the 
spliced peptide database size or structure. 
 
Comparison of sequence motifs in MHC-I immunopeptidomes 
In the MHC-I immunopeptidomes of nontumoral cells, spliced and non-spliced peptides 
differ in term of sequence motifs (9). This phenomenon could be due to the fact that 
PCPS seems to prefer sequence motifs in substrate polypeptides that are not those 
preferred for the normal peptide-bond hydrolysis (6).  After their generation by the 
proteasome, peptides are subjected to sequential steps of the antigen presentation 
pathway that select sequence motifs (15). We would therefore expect that sequence 
motifs of the MHC-I-bound spliced and non-spliced peptides would cluster together 
because the downstream steps of the antigen presentation pathway are the same. We 
also expect mild differences in the sequence motifs within the clusters because of the 
different preferences for substrate sequence motifs of peptide hydrolysis and PCPS 
reactions.  
Accordingly, we applied an in silico unsupervised approach to assign non-spliced peptides 
to the cancer cell lines’ MHC-I variants (Supplementary Table S1). We identified four 
non-spliced peptide clusters based on their amino acid characteristics (Fig. 2, 
Supplementary Fig. S4). When we assigned each spliced peptide to the cluster 
possessing the most similar characteristics, we found that: (i) spliced peptides could be 
clustered similarly to the non-spliced peptides in both cancer cells and significantly 
differently to randomly assigned sequences, (ii) the resulting clusters show similar cluster 
 statistics (Fig. 2A, Supplementary Fig. S4A), and (iii) the relative distribution of 
spliced and non-spliced peptides in the different clusters is similar (Fig. 2B, 
Supplementary Fig. S4B). However, specific sequence differences emerge, despite the 
common overall characteristics of the grouped spliced and non-spliced peptides (see also 
Supplemental Experimental Procedures for additional details). In fact, the amino acid 
frequencies vary slightly between the same cluster of the spliced and non-spliced 
immunopeptidomes (Fig. 2B, Supplementary Fig. S4B), confirming our initial 
hypothesis. Within the same cluster, the frequency of the P1 splicing-site (see 
Supplementary Fig. S1 for the nomenclature) does not always correspond to the 
intensity of the motif differences between spliced and non-spliced peptides. We find this 
unsurprising as residues around the P1 splicing-site seem to influence the PCPS efficiency 
(8). 
 
PCPS enlarges the antigenic landscape of cancer cell lines 
PCPS enlarges the antigenic landscape of cancer cells not only in terms of peptide variety 
in the immunopeptidomes but also in terms of the number of antigens presented by 
MHC-I-peptides. Indeed, almost 800 antigens identified in the MHC-I immunopeptidome 
of cancer cell lines are represented only by spliced peptides (Fig. 3A). These antigens 
could be targets for immunotherapies, if their expression is associated to the tumor or if 
they contain tumor-specific mutations. 
The 99% and 92% of non-spliced and spliced peptides, respectively, bound to MHC-I 
molecules are assigned to antigens detected at transcriptional level (Fig. 3B and 
Supplementary Table S6; see also Supplemental Experimental Procedures for 
additional details). Among the 97 spliced peptides, which putatively derive from antigens 
not detectable in the transcriptome, 18 could derive from antigens detectable in the 
transcriptome if we allowed intervening sequences longer than 25 residues. Furthermore, 
all the remaining spliced peptides can also derive from antigens detectable in the 
transcriptome if we allowed PCPS between different antigens, a phenomenon called trans 
PCPS (3) that is excluded in our human spliced proteome database. 
In terms of mutated antigens, 652 proteins that are identified at the RNA level in the 
HCT116 cell line (21) carry one or more missense mutations (22). Among them, 76% of 
the mutated antigens are not detected in the MHC-I immunopeptidome. The other 34%, 
on the contrary, is represented mainly by either spliced or non-spliced peptides, where 
the mutated antigens that are represented only by spliced peptides represent 5% of the 
mutated antigens’ pool in the MHC-I immunopeptidome of the HCT116 cell line (Fig. 3C 
left panel). Both spliced and non-spliced peptides more often represent mutated 
antigens (131 and 51 out of 695 mutated antigens are represented by non-spliced and 
spliced peptides, respectively, in the merged HCC1143 and HCT116 dataset) than non-
mutated antigens (2705 and 830 out of 21753 not mutated antigens are represented by 
non-spliced and spliced peptides, respectively, in the merged HCC1143 and HCT116 
 dataset; spliced peptide OR=2.0, p value=2.34*10-5; non-spliced peptides OR=1.6, p 
value=1.77*10-6). However, among those mutated antigens that are represented in the 
immunopeptidomes, only two mutations are actually carried by (non-spliced) peptides 
that have been identified in our analysis (Fig. 3D,E and Supplementary Table S3). 
These two neoepitopes, so named even though their recognition by T cells remains to be 
proved, are CHMP7[A324T]316-325 and RBBP7[N17D]12-20. Both efficiently bind HLA-
A*01:01 and HLA–B*18:01 molecules (Supplementary Table S3). Also, they can be 
generated by proteasome, as confirmed in in vitro digestions of the corresponding 
mutated antigenic polypeptide sequences carried out by the purified proteasome 
(Supplementary Fig. S5A,B, Supplementary Table S2; see also Supplemental 
Experimental Procedures). Transcription of both CHMP7 and RBBP7 antigens can be 
detected, as demonstrated in independent studies (21,22). Both antigens are 
represented in the MHC-I immunopeptidome by other non-spliced peptides, which, 
however, do not carry the mutations (Fig. 3D,E).  
The mutation load of the HCC1143 cell line is on the contrary much smaller (21,22) and 
none of the mutations are carried by spliced or non-spliced peptides. 
The fact that only 0.3% of the missense mutations (2 out of 695) is represented in the 
cancer cell lines’ MHC-I immunopeptidomes confirms that tumor-specific epitopes are 
rare. We speculate that their identification will be facilitated by also searching for spliced 
peptides, even though no tumor-specific spliced peptides have been detected in these 
cancer cell line MHC-I immunopeptidomes (possibly due to limited sample size). 
 
Common features of antigens in the cancer MHC-I immunopeptidomes 
Regarding the antigen features in the cancer cell lines’ MHC-I immunopeptidomes, the 
number of spliced peptides per antigen correlates with both antigen length (Fig. 4A) and 
intracellular abundance (Fig. 4B), as shown for non-spliced peptides (Fig. 4A, B), and 
by others (19,26,27). Furthermore, the MHC-I sampling probability (D), which considers 
the antigen length and indicates the likelihood of an antigen to be represented by a 
spliced peptide at the cell surface, increases for both spliced and non-spliced peptides 
with increasing antigen abundance (Fig. 4C, D and (19)). For those antigens that are 
represented by both spliced and non-spliced peptides, the spliced peptides’ D correlates 
with the non-spliced peptides’ D (Fig. 4E).  
As observed also for non-spliced peptides, the likelihood of an antigen being represented 
in these cancer cell lines by MHC-I-spliced peptide complexes is inversely correlated with 
the antigen half-life. This correlation has emerged by computing the fold over 
representation (D/D’), where D’ is the expected sampling probability, i.e. the average 
sampling probability of all antigens with the same abundance (see Supplemental 
Experimental Procedures for details). Indeed, the D/D’ ratio inversely correlates with the 
antigen half-life, independently of the half-life database used in the analysis (Fig. 4F). 
 
 Antigen features favoring antigen coverage by spliced peptides 
To identify antigenic features that result in efficient spliced peptide presentation 
independently of the cell types studied, we generated an extended immunopeptidome 
dataset by combining the datasets derived from the two cancer cell lines with that 
derived from the EBV-transformed lymphoblastoid cell line GR-LCL, which was generated 
by adopting a pre-fractioning of the peptide elution (2D strategy). The latter dataset is 
the most informative we have, because of the large number of identified peptides and 
the validation of the identifications by comparison with synthetic peptides (9). We re-
analyzed the GR-LCL 2D immunopeptidome dataset by applying SPI-delta. As expected, 
we identified a smaller number of spliced and non-spliced peptides (Supplementary 
Table S5), thereby confirming that SPI-delta is more stringent than the previous version 
(9) and results in larger numbers of non-annotated MS/MS spectra. 
From the extended MHC-I immunopeptidome dataset, 1096 antigens (almost 19% of all 
detected antigens) were identified that are represented by only spliced peptides (Fig. 
5A). This extended immunopeptidome accounts for 11655 unique peptides, of which 
9372 are non-spliced and 2283 are spliced peptides, the latter representing around 20% 
of the whole immunopeptidome variety. From this extended immunopeptidome dataset, 
we see that the presence of spliced peptides increases not only the number of antigens 
presented by MHC-I-peptides but also the number of peptides presented per antigen 
(Fig. 5A-B). 
With this extended dataset, derived from 16 different MHC-I haplotypes 
(Supplementary Table S1), we can study the spatial distribution of spliced and non-
spliced peptides by using a sliding window approach across the proteome and counting 
the number of observed peptides in each window (see Supplemental Experimental 
Procedures for details and Supplementary Fig. S6). We observed that spliced peptides 
cover a similar small fraction of the represented antigens compared to non-spliced 
peptides (Fig. 5C), although the presentation of both spliced and non-spliced peptides 
broadens the antigen coverage and the number of MHC-I-bound peptides per window 
(Fig. 5C,D). Furthermore, spliced peptides, like non-spliced peptides, cluster together in 
specific regions of the antigen, i.e. in “hotspots” (Fig. 5E). The observation that the 
coverage of spliced and non-spliced peptides together is smaller than the coverage of 
both peptide types individually (14% instead of 9.7%+7.2%=16.9%; Fig. 5D), indicates 
that they could be locally clustered together. Accordingly, the distances between spliced 
and non-spliced peptides are significantly smaller than the distances between randomly 
placed peptides (Fig. 5E and further details in Supplemental Experimental Procedures), 
hinting toward the existence of local antigenic regions prone to be represented by both 
spliced and non-spliced peptides. 
The question, however, remains: why are some antigens represented exclusively by only 
spliced or only non-spliced peptides, and, what characteristics differentiate them? 
 Antigens represented only by non-spliced peptides, for example, are significantly shorter 
than those presented only by spliced peptides or by both. More hydrophobic antigens are 
preferentially represented by spliced peptides than non-spliced peptides. Antigens 
represented only by non-spliced peptides show decreasing hydrophobicity with increasing 
antigen length. Conversely, antigens represented only by spliced peptides have generally 
higher hydrophobicity than those represented only by non-spliced peptides, 
independently of their length, and have decreasing hydrophobicity with the increase of 
the length, although only until a length of approximately 1000 residues (Fig. 6A).  
The average isoelectric point (IP) of antigens represented only by spliced peptides does 
not differ compared to those antigens represented only by non-spliced peptides, or 
represented by both types of peptides (Fig. 6B). However, clear differences emerge 
when considering the whole trimodal IP distribution - for which the average is not 
representative - and computing the so-called IP bias (Fig. 6C,D; see Supplemental 
Experimental Procedures for detail analysis). This latter analysis suggests that spliced 
peptides are generated more efficiently from basic antigens than from acidic antigens.  
In summary, length, hydrophobicity and IP of an antigen are parameters that can 
determine whether an antigen is represented by MHC-I-spliced peptide complexes or not.  
The two antigens from which we have identified non-spliced peptides carrying a tumor-
specific mutation, CHMP7 and RBBP7, have characteristics that favor their representation 
through non-spliced peptides only. They are relatively short (453 and 425 amino acids, 
respectively), are rather hydrophilic (hydrophobicity index of -0.48 and -0.53, 
respectively) and acidic (isoelectric point of 4.99 and 4.68, respectively), all 
characteristics disfavoring the representation by spliced peptides. Indeed, we did not 
detect any spliced peptide representing these two antigens. 
 
Discussion 
Despite the limited knowledge about PCPS, identification of CD8+ T cells specific towards 
spliced epitopes and able to reduce tumor growth (13,14) hint at the value of spliced 
epitopes as targets for anti-cancer ATTs. This hypothesis is now supported by our 
demonstration here that in the breast and colon cancer cell lines, around 20% of the 
MHC-I immunopeptidome variety and quantity seems to be represented by spliced 
peptides.  
This estimation depends on the technique and the statistics adopted. Indeed, the 
identification of spliced peptides in the immunopeptidome presents technical issues that 
need to be considered (15). To tackle the technical implications of the large spliced 
peptide database of the human proteome, we developed and applied in this study an 
amended identification pipeline (SPI-delta) that is stringent in term of identification 
confidence. For example, from the analysis of the same four MS replicates of the MHC-I 
immunopeptidome of the HCT116, Bassani-Sternberg and co-workers (19) identified five 
non-spliced neoepitopes, whereas only two of them passed our pipeline. Our results  
 show that the increase in stringency in our identification strategy has resulted in less 
sensitivity for the identification of non-spliced and spliced peptides. 
Another aspect to consider is that the success in peptide identification correlates, for both 
spliced and non-spliced peptides, with the number of replicates analyzed. However,  we 
found spliced peptides were less common in the cancer cell line immunopeptidomes than 
non-spliced peptides, as we previously observed in non-cancer immunopeptidomes (9). 
Therefore, the correlation is stronger for spliced peptides. 
Despite our stringent pipeline, our two control experiments indicate that we still have an 
experimental FDR for spliced peptide identification of about 2-4%, and for non-spliced 
peptides of about 1%. However, none of our controls are completely free of spliced 
peptides. Indeed, Lys-C and trypsin can also catalyze peptide splicing (3,28). 
Furthermore, several among the peptides assigned as spliced peptides using the inverted 
splice-reactant database could be the outcome of PCPS reaction between non-contiguous 
peptides either with intervening sequences longer than 25 residues or derived from 
distinct antigens (i.e. trans spliced peptides). Thus, we cannot exclude the possibility of 
false identification for some of the peptides assigned as spliced peptides in our control 
experiments.  
The same concept is applicable to the group of spliced peptides that, according to our 
mapping, are derived from antigens not detected as transcripts: several of them could be 
derived from antigens detected in the cancer cell transcriptome if we allowed intervening 
sequences longer than 25 residues and all of them could be the product of trans PCPS 
involving two antigens detected in the cancer cell transcriptome. 
The exclusion of spliced peptides derived from either trans PCPS or cis PCPS with long 
intervening sequences, which was based on a preliminary study on one spliced epitope 
(29), could be misleading in the analysis of the entire MHC-I spliced immunopeptidome, 
as suggested by Faridi et al. (30). For example, we do not observe a correlation between 
the number of unique spliced peptides and their intervening sequence length. In the 
future, this restriction could be solved by adopting a de-novo sequencing strategy in the 
identification pipeline, for instance, as been done by Faridi et al. (30). 
The general picture that emerges from our study points out that a large portion of the 
MHC-I immunopeptidome is populated by spliced peptides in cancer cell lines. Particularly 
relevant for anti-cancer immunotherapy could be the fact that PCPS allows 
representation of antigens that otherwise would be overlooked. For example, around one 
fourth of mutated antigens represented in the immunopeptidome of colon cancer cell line 
is represented only by spliced peptides, which could be relevant when searching for 
target neoepitopes and neoantigens suitable for ATTs. The antigens that are represented 
at the cell surface by spliced peptides are preferentially long, hydrophobic and basic. Why 
those antigens have those characteristics warrants further investigation. However, we 
speculate that short antigens are less likely to produce spliced peptides simply due to 
less combinatorial possibilities. Furthermore, spliced peptides can be produced more 
 easily if more hydrophobic amino acid residues are present in the antigen (8), since the 
C-terminal splice-reactant competes with a molecule of water for the nucleophilic attack 
to the acyl-enzyme intermediate (4). On the other hand, in non-spliced peptides less 
hydrophobic antigens are preferred, since the interaction with water molecules is needed 
for proteasomal peptide-bond hydrolysis. This means that the longer an antigen is, the 
more hydrophilic residues it needs to produce mainly non-spliced peptides. And, the 
longer an antigen is, the higher is the chance it would generate spliced peptides and the 
hydrophobicity could be progressively lower. There is, however, a hydrophobicity 
threshold, which is on average around 0.48 (hydrophobicity index) in our dataset, below 
which antigen hydrophobicity would favor the production of non-spliced peptides. 
Therefore, once the antigens represented only by spliced peptides reach that threshold 
they start to increase their average hydrophobicity. 
In weighing the pros and cons of targeting spliced epitopes by anti-cancer ATTs, we shall 
consider that spliced peptides cluster similarly to non-spliced peptides with respect to 
amino acids characteristics. Some mild differences in the spliced and non-spliced 
sequence motifs are detectable in the cancer immunopeptidomes. On one hand this 
result confirms the hypothesis that spliced peptides follow the same antigen presentation 
pathway as non-spliced peptides and are selected by their affinity to the MHC-I cleft. On 
the other hand, it underlines that spliced peptides are different from non-spliced 
peptides. Indeed, PCPS is a very different process from peptide hydrolysis, which seems 
to follow different rules and to be driven by different factors (3,6,8). Only by 
understanding in detail those factors and dynamics, could we predict spliced peptide 
generation and streamline our efforts by targeting those spliced (neo)epitope candidates 
that most likely are efficiently produced and presented.  
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Figure legends 
 
Figure 1. Size of the MHC-I spliced and non-spliced immunopeptidomes of colon 
and breast carcinoma cell lines and related controls. (A) Number of spliced and 
non-spliced peptides identified in the MHC-I immunopeptidomes of HCT116 and HCC1143 
cell lines, as well as their combined dataset. In the upper panel, we report the absolute 
and relative frequency of spliced and non-spliced peptides considering the mutations 
detected in the two cell lines and several PTMs. The latters were allowed only for the 
non-spliced peptide database. However, we report here the absolute and relative 
frequency of non-spliced peptides not post-translationally modified to be comparable to 
spliced peptides (also not carrying PTM). In the lower panel, we report the absolute and 
relative frequency of spliced and non-spliced peptides not considering the mutations 
detected in the two cell lines and PTMs. (B) Distribution of the MS ion peak area of 
spliced and non-spliced peptides in the HCT116 and HCC1143 immunopeptidomes 
measured by label-free quantification. The MS ion peak area distribution of the non-
spliced peptides is significantly larger than the distribution of spliced peptides in both 
immunopeptidomes (Kolmogorov-Smirnov test; HCC1143 p-value: 0.00156; HCT116 p-
value: 0.03). The total abundance of spliced peptides calculated from the integral of the 
MS ion peak areas of spliced peptides relative to the integral of the peak area of all 
peptides is reported. The number of identified peptides and the MS ion peak area 
correlates significantly with the number of biological replicates in which they are 
identified (see Supplementary Fig. S3B-E). (C) Frequency of spliced and non-spliced 
peptides detected in the LysC-trypsin digestion of the HCC1143 intracellular proteasome-
unprocessed proteome. Proteins larger than 30kDa have been separated from the cell 
lysate of the HCC1143 cell line - to eliminate protein fragments already produced by 
proteasome – and digested by LysC and trypsin. The resulting sample has been analyzed 
by MS using the same data analysis strategy used for the MHC-I immunopeptidomes. 
Shown are the number and frequencies of spliced and non-spliced peptides assigned in 
the LysC/trypsin-processed proteome dataset (n=1). (D) Comparison of peptide length 
distribution identified in the HCC1143 immunopeptidome (left panel) and the 
LysC/trypsin-processed intracellular proteome (right panel). (E) Comparison of the 
detected precursor charge distribution of the HCC1143 immunopeptidome and the 
LysC/trypsin-processed intracellular proteome. (F) Frequency of detected semi-inverted 
spliced peptides (green/ yellow) compared to frequency of non-spliced and spliced target 
peptides identified in one technical replicate of the HCT116 immunopeptidome. Indicated 
percentages are relative to the total number of peptides assigned in each experiment. 
The frequency of identification of semi-inverted spliced peptides is an estimation of the 
frequency of wrongly annotated spliced and non-spliced peptide sequences. Yellow 
indicated fractions are semi-inverted peptide sequences, which could also be explained 
 as target cis spliced peptides with intervening sequence length longer than 25 residues 
(see Materials & Methods). 
 
Figure 2. Sequence motifs of the MHC-I spliced and non-spliced 
immunopeptidome of the colon carcinoma cell line. (A) Distribution of the distances 
within the cluster of non-spliced peptides (orange line), between spliced and non-spliced 
peptides (blue line) and between non-spliced peptides and control random peptides (grey 
line) in the 4 clusters of the spliced and non-spliced peptides identified in the MHC-I 
immunopeptidome of the HCT116 cell line. The lower panel shows the Kolmogorov-
Smirnov distance between the distributions of non-spliced and spliced peptides and 
control peptides, respectively, which are significantly different (Kolmogorov-Smirnov 
test; p-value = 0.03). (B) Comparison of the amino acid frequencies for each position of 
the non-spliced and spliced 9mer peptides of the HCT116 MHC-I immunopeptidome, after 
clustering according to their amino acid features. For each of the 4 clusters, amino acid 
frequencies are shown in the left panels. The size of the amino acid letters corresponds 
to their occurrence within the cluster. The number of peptides belonging to each cluster 
and their relative frequency are also reported. On the right panels, the motifs’ difference 
between the amino acid frequencies of the non-spliced and spliced 9mer peptides is 
reported as Jensen-Shannon (JS) divergence. The inlets on the top of the right panels 
show the frequency of PCPS (as P1 position) for each residue. The HLA-I alleles 
corresponding to each cluster are reported, and they have been identified by similarities 
with known HLA-I-specific peptide sequence motifs. 
 
Figure 3. PCPS enlarges the antigenic landscape of the two cancer cell lines. 
Data refer to the peptides identified in the MHC-I immunopeptidomes of the HCT116 and 
HCC1143 cell lines, which is reported as a combined analysis of the two datasets in 
(A,B). (A) Number of antigens represented by only spliced peptides, by only non-spliced 
peptides, or by both in the immunopeptidome. (B) Number and frequency of sequences 
that are present in the immunopeptidomes and that derive from antigens also detected 
in the cancer cell line transcriptomes (21), considering separately antigens represented 
by spliced or non-spliced peptides. (C) Prevalence of HCT116 and HCC1143 mutated 
proteins represented (or not represented) on MHC-I complexes by either spliced 
peptides, non-spliced peptides, or both. The frequencies refer to either proteins that 
were detected at the RNA level and have missense mutations (left panels) or proteins 
that were detected at RNA level regardless their mutational load (right panels). (D,E) 3D 
structures of the antigens CHMP7 (D), and RBBP7 (E), from which 5 non-spliced peptides 
were identified in the HCT116 immunopeptidome, including the two non-spliced 
neoepitopes CHMP7[A324T]316-325 and RBBP7[N17D]12-20. The structures were predicted 
using i-Tasser server. The non-spliced peptides (including the non-spliced neoepitopes) 
are labeled in orange.  
  
Figure 4. Relationship between antigen length, abundance and half-life detected 
in the cancer cell lines and their probability of representation as MHC-I-spliced 
peptides. Data refer to the antigenic peptides identified in the MHC-I 
immunopeptidomes of the HCT116 and HCC1143 (here reported as a combined analysis 
of the two datasets). (A) Correlation between the number of spliced or non-spliced 
peptides detected in the immunopeptidomes and the antigen length (non-spliced 
peptides: C=0.15, p-value< 10-16; spliced peptides: C=0.15, p-value< 10-16). (B) 
Correlation between the number of spliced (light blue dots) or non-spliced (orange dots) 
peptides per antigen and the antigen abundance as measured by Bassani-Sternberg et 
al. (19) in the cell lysates. Dark blue lines and red lines indicate a running average of the 
peptide numbers over the antigen abundance. Both the number of spliced and non-
spliced peptides is correlated with antigen abundance (non-spliced: C = 0.7, p value < 
10-16; spliced peptides: C = 0.4, p = < 10-16). In (A,B) the Y-axis is in log scale. (C) 
Relationship between the number of theoretically possible 9mer spliced or non-spliced 
peptides, respectively, and the antigen length. The number of non-spliced peptides has 
been computed as N = antigen length – 8 (red line). The number of unique spliced 
peptides in the human proteome spliced peptide database was counted and could be 
approximated by linear regression (dark blue line) with n = 399.12*antigen length – 
7948.4 (p-value < 10-16 for both estimated parameters using linear regression in R). The 
dashed green line indicates the ratio of the number of spliced peptides over the number 
of non-spliced peptides, which asymptotically reaches 398 for antigens longer than 500 
amino acids. (D) Correlation between the MHC-I peptide sampling probability (D) and the 
antigen intensity measured in the intracellular proteome (19). (E) Correlation between 
the spliced peptide sampling density and the non-spliced peptide sampling density (C = 
0.7, p value < 10-16). (F) Relationship between the fold over representation (D/D’) and 
the antigen half-life, using half-lives based on Boisvert et al. (31), or McShane et al. 
(32). Only antigens identified in the intracellular proteome of the HCT116 and HCC1143 
cell lines by Bassani-Sternberg  et al. (19) have been included here. 
 
Figure 5. Spliced peptides broaden the antigens’ coverage of tumor and 
nontumor cell lines and locally cluster with non-spliced peptides in antigen hot 
spots. The values refer to the extended human MHC-I self-immunopeptidome, which 
includes the immunopeptidomes of HCT116 and HCC1143 cancer cell lines, and GR-LCL. 
(A) Number of antigens represented by only spliced peptides, only non-spliced peptides, 
or both. Among all identified antigens, 1096 antigens are represented by 1197 unique 
spliced peptides, 3850 antigens are represented by 6987 non-spliced peptides and 910 
antigens are represented by both spliced (n=1095) and non-spliced (n=2481) peptides. 
(B) Frequency of non-spliced peptides, spliced peptides, or any peptide per antigen. (C) 
Coverage of the antigen sequences by either non-spliced peptides, spliced peptides, or 
 both considering a 25 or 50 residue window, respectively. (D) Distribution of the number 
of antigenic peptides (non-spliced, spliced or both) per window (using a 50-residue 
window). Percentage represents antigen coverage. (E) Measured distance between either 
non-spliced peptides, spliced peptides, or between spliced and non-spliced peptides. The 
red lines represent the respective random distributions, for which no local clustering can 
be observed and which significantly differs from the distribution of the distance of the 
peptides identified in the MHC-I immunopeptidomes (Mann-Whitney test p-values are 
shown).  
 
Figure 6. Antigens represented by either spliced or non-spliced peptides have 
different characteristics. The values refer to the extended human MHC-I self-
immunopeptidome, which includes the immunopeptidomes of HCT116 and HCC1143 
cancer cell lines, and GR-LCL. (A) Correlation between the average hydrophobicity and 
length for the antigens represented by non-spliced peptides (tan line), spliced peptides 
(blue line), or both (grey line), and antigens not represented in the extended MHC-I self-
immunopeptidome (black line). Running averages are shown. (B) Correlation between 
the average IP and length for antigens represented by non-spliced peptides (tan line), 
spliced peptides (blue line), or both (grey line, and antigens not represented in the 
extended MHC-I self-immunopeptidome (black line). Running averages are shown. (C) 
Distributions of computed IPs for all antigens represented by either non-spliced peptides, 
spliced peptides, or both. All three groups show trimodal distributions (grey histograms), 
which could be approximated as a Gaussian mixture model (black line) consisting of 
three Gaussian distributions with differing mean and standard deviations (red, yellow and 
green lines). The two Gaussian distributions with average IP < 7 (red and yellow lines) 
include the acidic set of antigens, whereas the Gaussian distribution with average IP > 7 
(green lines) include the set of basic antigens. (D) IP-bias (isoelectric point bias) for 
antigens represented by either non-spliced peptides, spliced peptides, or both. The IP-
bias is the proportion of antigens that fall into the basic set compared to the acidic set 
(color scheme corresponds to C). 
 






